N/A N=98 Pilot Intervention to Empower HIV Clients as Prevention Advocates in Uganda
HIV
Primary: Change in Engagement HIV Prevention Advocacy — 4.1; 3.8; 4.2; 3.5 units on a scale — p=.017
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=14 Botulinum Toxin Type A Injection After Topical Anesthesia Versus Petrolatum Ointment
Forehead Rhytides · Forehead Wrinkles
Primary: Eyebrow Excursion — 10.57; 10.57 millimeters
Phase 2 N=205 A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Primary: Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) — 0; 29.4; 58.8; 66.7 percentage of participants — p=0.009
N/A N=36 Stereotactic Body Radiotherapy for Spine Tumors
Spinal Metastases · Vertebral Metastases · Benign Spinal Tumors
Primary: Initial Symptom Control — 3; 28; 3; 27 Participants
Phase 3 N=88 Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia
Dementia · Alzheimer's Disease
Primary: Quality of Life Scale in Alzheimer's Disease (QOL-AD) — 38.8; 40.0 score on a scale — p=0.14
N/A N=273 New Dermal Filler for Lip Augmentation
Lip Augmentation
Primary: Assess Effectiveness of the Treatment Using the Medicis Lip Fullness Scale (MLFS) — 1.8; 1.7; 1.8; 1.8 Change in MLFS score from baseline
N/A N=126 Comparison of Colon Adenoma Detection Rate Using Two Distal Colonoscope Attachments
Colon Cancer Screening · Colon Polyps · Colon Adenomas
Primary: Adenoma Detection Rate — 52.4; 40.5; 54.8 percentage of adenomas detected
N/A N=200 Urinalysis Results in Healthy Individuals
Asymptomatic Bacteriuria · Asymptomatic Pyuria
Primary: False Positive Urine — 6; 40 Participants
N/A N=52 A Dispensing Comparison of a Test Daily 1 Day Lens Against a Control 1 Day Lens.
Myopia
Primary: Number of Participants With Lens Centration — 17; 12; 34; 39 Participants
Phase 1 N=42 A Study of LY900014 in Participants With Type 1 Diabetes Mellitus
Type 1 Diabetes Mellitus
Primary: Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) Following Each Treatment Arm for Each Study Part — 755; 754; 962; 908 Picomoles*hour/Liter…
Phase 3 N=1,147 Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Breast Cancer
Primary: Progression Free Survival (PFS) Based on Local Investigator Assessment - Full Analysis Set (FAS) in Full Population, Main Study Cohort and PI3K Unknown Cohort — 6.9…
Phase 2 N=99 Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.
Carcinoma, Renal Cell
Primary: Probability Rates of Progression-free Survival at 9 Months — 0.431; 0.452 Probability — p=0.8531
N/A N=427 Life Plans Intervention Study
HIV/AIDS · Chronic HIV Infection · Health Knowledge, Attitudes, Practice
Primary: Number of Participants Who Participated in HIV Testing — 69; 33; 46 Participants
N/A N=16 Analgesic Value of Adductor Canal vs Femoral Block After Total Knee Arthroplasty
Osteo Arthritis Knee
Primary: Pain Intensity as Measured by 11-point Verbal Numeric Rating Scale (NRS-11) for Pain. — 7.0; 6.0; 4.0; 6.0 units on a scale
Phase 2 N=29 Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
Pancreatic Alpha Cell Carcinoma · Pancreatic Beta Islet Cell Carcinoma · Pancreatic Delta Cell Carcinoma
Primary: Determine the Maximum Tolerated Dose (MTD) of Temozolomide in Combination With 400 mg Pazopanib in Patients With Advanced Pancreatic Neuroendocrine Tumor (PNET) in Phase…